PFKFB3 and gastric cancer: PFKFB3 inhibitor 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) and its derivation 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK15) have been confirmed to inhibit glucose metabolism and exert potent antitumor activity in multiple cancers, especially gastric cancer [42,43].